Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aquestive Therapeutics, Inc.AQST · Entity 5276 | Chief Commercial Officer | September 09, 2026 | September 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aquestive Therapeutics, Inc.
Report date September 09, 2026 · Filed September 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 235,689 |
Ending reported balance
After 2026-09-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-09 · Exercise / conversion · Acquired 8,750 · Balance 244,439 Row 2 · 2026-09-09 · Sale · Disposed 8,750 · Balance 235,689 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.65 · Expires 2035-03-07 | Direct | 26,250 |
Reported balance
After 2026-09-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-09 · Exercise / conversion · Disposed 8,750 · Balance 26,250 F2: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4.
F2: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 09, 2026 Filed Sep 11, 2026 15:07 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 8,750 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001214659-26-011596 · marketforms-73981.xml · derivative · entry 3 Korczynski Sherry · CIK 0002026090 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 8,750 shares Expires 2035-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 15:07 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | SaleCommon Stock | 8,750 | $5.22 | $45,675.00 |
DisclosureSEC source: 0001214659-26-011596 · marketforms-73981.xml · nonDerivative · entry 2 Korczynski Sherry · CIK 0002026090 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 235,689 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 15:07 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 8,750 | $2.65 | $23,187.50 |
DisclosureSEC source: 0001214659-26-011596 · marketforms-73981.xml · nonDerivative · entry 1 Korczynski Sherry · CIK 0002026090 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 244,439 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 14, 2026 Filed Aug 17, 2026 21:33 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 2,714 | $4.25 | $11,534.50 |
DisclosureSEC source: 0001214659-26-010474 · marketforms-73774.xml · nonDerivative · entry 1 Korczynski Sherry · CIK 0002026090 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,689 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Read SEC document |
| June 08, 2026 Filed Jun 9, 2026 18:48 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 2,714 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-26-007262 · marketforms-73366.xml · nonDerivative · entry 1 Korczynski Sherry · CIK 0002026090 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 238,403 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 16:51 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | SaleCommon Stock | 15,741 | $4.17 | $65,687.19 |
DisclosureSEC source: 0001214659-26-003142 · marketforms-72468.xml · nonDerivative · entry 2 Korczynski Sherry · CIK 0002026090 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 241,117 F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $4.17 to $4.32. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 16:51 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 42,500 | $4.29 Strike: $4.29 | $182,325.00 |
DisclosureSEC source: 0001214659-26-003142 · marketforms-72468.xml · derivative · entry 3 Korczynski Sherry · CIK 0002026090 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 42,500 shares Expires 2036-03-09 F4 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 16:51 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-26-003142 · marketforms-72468.xml · nonDerivative · entry 1 Korczynski Sherry · CIK 0002026090 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 256,858 F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| August 14, 2025 Filed Aug 15, 2025 12:41 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-25-012304 · marketforms-70071.xml · nonDerivative · entry 1 Korczynski Sherry · CIK 0002026090 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,858 F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| June 09, 2025 Filed Jun 10, 2025 18:12 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 2,714 | $3.54 | $9,607.56 |
DisclosureSEC source: 0001214659-25-009047 · marketforms-69905.xml · nonDerivative · entry 1 Korczynski Sherry · CIK 0002026090 · SVP Sales and Marketing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,858 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 21:48 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001214659-25-004224 · marketforms-68572.xml · derivative · entry 3 Korczynski Sherry · CIK 0002026090 · SVP Sales and Marketing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2035-03-07 F3 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 21:48 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 5,428 | $2.65 | $14,384.20 |
DisclosureSEC source: 0001214659-25-004224 · marketforms-68572.xml · nonDerivative · entry 2 Korczynski Sherry · CIK 0002026090 · SVP Sales and Marketing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 159,572 F2 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 21:48 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantCommon Stock | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-25-004224 · marketforms-68572.xml · nonDerivative · entry 1 Korczynski Sherry · CIK 0002026090 · SVP Sales and Marketing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,000 F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| March 07, 2025 Filed Apr 13, 2026 19:52 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantPerformance Stock Units · Derivative | 67,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-26-004593 · marketforms-72933.xml · derivative · entry 1 Korczynski Sherry · CIK 0002026090 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,500 Underlying: Common Stock · 67,500 shares Expires 2028-03-07 F1 · security: This Form 4 was filed late due to an inadvertent administrative oversight. F2 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Company's common stock. The PSUs measure performance from March 7, 2025 (Grant Date) through March 7, 2028 and, if earned, vest 100% on March 7, 2028. "Performance Price" means (i) the 30-day average Nasdaq closing price ending on the last day of the period from the Grant Date through the day before the second anniversary (First Pricing Period) and (ii) the highest 30-day average Nasdaq closing price during the period from the second through the third anniversary (Second Pricing Period). F2 · derivative.exercise_date: Each PSU represents a contingent right to receive one share of the Company's common stock. The PSUs measure performance from March 7, 2025 (Grant Date) through March 7, 2028 and, if earned, vest 100% on March 7, 2028. "Performance Price" means (i) the 30-day average Nasdaq closing price ending on the last day of the period from the Grant Date through the day before the second anniversary (First Pricing Period) and (ii) the highest 30-day average Nasdaq closing price during the period from the second through the third anniversary (Second Pricing Period). Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 16:36 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-24-010798 · marketforms-66306.xml · nonDerivative · entry 1 Korczynski Sherry · CIK 0002026090 · SVP Sales and Marketing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.